CPL'36 Shows Promising Results in Schizophrenia Trial, Set for Phase 3

In a significant advancement for psychiatric medicine, Celon Pharma has announced that its novel antipsychotic compound, CPL'36, demonstrated a statistically significant 16.4-point reduction in Positive and Negative Syndrome Scale (PANSS) scores after just four weeks of treatment in a Phase 2 clinical trial—outperforming placebo and suggesting a potentially superior efficacy profile compared to existing schizophrenia therapies.

CPL'36 is a selective inhibitor of phosphodiesterase 10A (PDE10A), an enzyme highly concentrated in the striatum, a brain region critical for motor control, motivation, and cognitive processing—all areas implicated in schizophrenia pathology. Unlike conventional antipsychotics that primarily target dopamine D2 receptors, CPL'36 modulates intracellular signaling pathways downstream of both dopamine and glutamate receptors, offering a more nuanced approach to symptom management without the same burden of motor side effects such as tardive dyskinesia or extrapyramidal symptoms.

According to a press release from BioSpace, the FDA has granted clearance for Celon Pharma to advance CPL'36 into Phase 3 clinical trials, a pivotal step toward potential regulatory approval. The Phase 2 results, while preliminary, have drawn attention from neuroscientists and clinicians alike for their magnitude and speed of improvement. A 16.4-point PANSS reduction is notably higher than the typical 10-12 point reductions seen with second-generation antipsychotics like risperidone or olanzapine over similar timeframes, suggesting CPL'36 may offer a more robust therapeutic effect.

Importantly, early safety data indicate a favorable tolerability profile. No significant increases in weight gain, metabolic disturbances, or prolactin elevation—common adverse effects of current antipsychotics—were reported in the trial cohort. This could address one of the most persistent challenges in schizophrenia care: patient non-adherence due to debilitating side effects. If replicated in larger populations, CPL'36 may not only improve symptom control but also enhance long-term treatment retention and quality of life.

Dr. Elena Márquez, a neuropsychopharmacologist at the National Institute of Mental Health, commented, "This is one of the most compelling PDE10A inhibitors we've seen in over a decade. The mechanism targets core circuit dysfunction in schizophrenia, not just downstream neurotransmitter imbalances. If Phase 3 confirms these findings, we may finally have a drug that addresses both positive and negative symptoms with minimal metabolic risk."

The global burden of schizophrenia affects approximately 24 million people worldwide, with current treatments often failing to fully resolve negative symptoms—such as social withdrawal, anhedonia, and cognitive deficits—that are most disabling over time. CPL'36’s potential to ameliorate these symptoms, in addition to hallucinations and delusions, could represent a major leap forward.

Celon Pharma has not disclosed full trial data publicly, but sources indicate the Phase 2 study involved over 180 participants across multiple U.S. and European sites. The company plans to initiate Phase 3 trials in early 2025, with enrollment expected to exceed 1,000 patients. Regulatory pathways are being coordinated with both the FDA and the European Medicines Agency.

While optimism is warranted, experts caution against premature enthusiasm. Past PDE10A inhibitors, such as TAK-063 and MP-10, showed promise in early trials but failed to replicate benefits in larger studies. The success of CPL'36 will depend on rigorous validation in diverse populations, longer-term safety monitoring, and comparison against active comparators—not just placebo.

For patients and families long accustomed to incremental improvements in schizophrenia care, CPL'36 represents a beacon of hope. If successful, it could usher in a new generation of precision neurotherapeutics—targeting the biological roots of psychosis rather than merely suppressing its symptoms.